Navigation Links
EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
Date:12/9/2008

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients. The study will be conducted at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. Dr. Sherif Farag, Associate Professor, Department of Medicine, will serve as principal investigator.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Primary objectives for the dose escalation study include determining the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ENMD-2076 when administered orally once a day in patients with multiple myeloma who are refractory to other drug therapy. The study will also assess the safety, tolerability, pharmacodynamic effects and activity of ENMD-2076 in this patient population.

Preclinical data supporting the clinical evaluation of ENMD-2076 alone and in combination in multiple myeloma were presented by Dr. Farag earlier this week at the American Society of Hematology Annual Meeting in San Francisco, CA. ENMD-2076 was shown to induce rapid apoptosis (cell death) in multiple myeloma cell lines in vitro. Significant dose-dependent antitumor activity with minimal toxicity was also induced in vivo when ENMD-2076 was administered as a single agent in multiple myeloma models. Combination studies with ENMD-2076 and lenalidomide (Revlimid(R)) in vitro indicated synergistic cytotoxic activity towards several human multiple myeloma cell lines. ENMD-2076 was shown, both in vitro and in vivo, to have minimal toxicity towards human and murine hematopoietic progenitor cells, which are essential for maintenance of an active immune system.

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. In addition, ENMD-2076 is relatively selective for the Aurora A isoform in comparison to Aurora B. ENMD-2076 has shown significant cytotoxic activity preclinically towards a variety of human leukemia and myeloma cell lines, as well as towards ex vivo-treated human leukemia patient samples.

EntreMed Vice President of Research, Mark R. Bray, Ph.D., commented, "With our ongoing study in solid tumors progressing well, coupled with the initiation of the multiple myeloma study, our ENMD-2076 program is gaining substantial momentum. The work of Dr. Farag and his colleagues has provided important insights into the mechanism of action of ENMD-2076, and has strongly supported the rationale for clinical investigation of the drug candidate in hematologic malignancies such as multiple myeloma."

Carolyn F. Sidor, M.D., M.B.A., Vice President and Chief Medical Officer, commented on the Phase 1 study, "Initiation of this Phase 1 study represents continued advancement of the ENMD-2076 clinical program. We are encouraged by the significant preclinical activity we have observed with ENMD-2076 in both solid and hematologic tumors. Based on our cumulative preclinical data, we believe that ENMD-2076 may provide clinical benefit in a broad range of malignancies. We anticipate commencement of a second Phase 1 study in hematological cancers early next year."

To view a copy of Dr. Farag's poster, visit the Company's web site at http://www.entremed.com.

Revlimid(R) a registered trademark of Celgene Corporation and not the Company.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

     CONTACT:
     Ginny Dunn
     Associate Director, Corporate Communications & Investor Relations
     EntreMed, Inc.
     240.864.2643

'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 , ... ... re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC ... new tools and assays, and their applicability in drug safety assessment, for the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... and epigenetics research, recently announced a collaboration with the Heidelberg University Hospital and ... method for library preparation, following the company’s successful launch of its CATS ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... MANHASSET, N.Y. , Jan. 16, 2017   ... Kevin J. Tracey, MD , president and CEO of ... Northwell Health, completed an analysis of how the nervous ... further identify and develop bioelectronic medicine devices ... today in Nature Neuroscience . The ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):